BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 18835576)

  • 1. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
    Lahiri A; Das P; Chakravortty D
    Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs targeting Toll-like receptors.
    Krishnan J; Lee G; Choi S
    Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.
    Ketloy C; Engering A; Srichairatanakul U; Limsalakpetch A; Yongvanitchit K; Pichyangkul S; Ruxrungtham K
    Vet Immunol Immunopathol; 2008 Sep; 125(1-2):18-30. PubMed ID: 18571243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants and autoimmunity.
    Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
    Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors' two-edged sword: when immunity meets apoptosis.
    Salaun B; Romero P; Lebecque S
    Eur J Immunol; 2007 Dec; 37(12):3311-8. PubMed ID: 18034428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor ligands energize peptide vaccines through multiple paths.
    Celis E
    Cancer Res; 2007 Sep; 67(17):7945-7. PubMed ID: 17804699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TLR based therapeutics.
    Dunne A; Marshall NA; Mills KH
    Curr Opin Pharmacol; 2011 Aug; 11(4):404-11. PubMed ID: 21501972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptors and innate immunity.
    Kumar H; Kawai T; Akira S
    Biochem Biophys Res Commun; 2009 Oct; 388(4):621-5. PubMed ID: 19686699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention].
    Kabelitz D
    Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of the innate immune system in domestic animals.
    Coffey TJ; Werling D
    Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating vaccine responses with dendritic cells and Toll-like receptors.
    Pulendran B
    Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell-dependent and -independent IgA responses: role of TLR signalling.
    Bessa J; Bachmann MF
    Immunol Invest; 2010; 39(4-5):407-28. PubMed ID: 20450285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic and therapeutic implications of toll-like receptor ligands.
    Hedayat M; Takeda K; Rezaei N
    Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Toll-like receptors].
    Essakalli M; Atouf O; Bennani N; Benseffaj N; Ouadghiri S; Brick C
    Pathol Biol (Paris); 2009 Jul; 57(5):430-8. PubMed ID: 18513891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous TLR ligands and autoimmunity.
    Wagner H
    Adv Immunol; 2006; 91():159-73. PubMed ID: 16938540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.